Save 20% on Press Releases and More with NNW Prime! Click to View Details
WednesdaySep 27, 2017 10:00 am

Power Clouds, Inc. (PWCL) Starts Presentation at the 2017 Disruptive Growth Company Showcase

Power Clouds (OTC: PWCL) is a global renewable energy provider engaged in owning and operating clean energy power plants in multiple countries where the combination of regulatory, economic and environment elements are maximized. The company functions by operating solar parks that connect directly to national power grids rather than residential rooftops. The company’s global focus results in operations that are not limited to any one geography, single commercial model or regulatory influence. For more information, visit the company’s website at www.powercloudsInc.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers,…

Continue Reading

WednesdaySep 27, 2017 9:30 am

Heat Biologics, Inc. (NASDAQ: HTBX) Starts Presentation at the 2017 Disruptive Growth Company Showcase

Heat Biologics (NASDAQ: HTBX) is a biopharmaceutical company developing novel therapies designed to activate a patient’s immune system against cancer using its CD8+ "Killer" T-cells. The company is currently enrolling patients in its phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). The company also has numerous pre-clinical programs at various stages of development. For more information, visit the company’s website at www.heatbio.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services,…

Continue Reading

WednesdaySep 27, 2017 9:30 am

MagneGas Corp. (NASDAQ: MNGA) Starts Presentation at the 2017 Disruptive Growth Company Showcase

MagneGas (NASDAQ: MNGA) owns a patented process that converts various renewables and liquid wastes into MagneGas fuels, which can be used as an alternative to natural gas or for metal cutting. The company’s tests of “MagneGas2®” metal cutting fuel validated the advantages of the cleaner, faster, more productive fuel. The company currently sells MagneGas2® into the metal working market as a replacement to acetylene. The company also sells equipment for the sterilization of bio-contaminated liquid waste for various industrial and agricultural markets. For more information, visit the company’s website at www.magnegas.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that…

Continue Reading

WednesdaySep 27, 2017 9:00 am

Overstock.com, Inc. (NASDAQ: OSTK) Starts Presentation at the 2017 Disruptive Growth Company Showcase

Overstock.com (NASDAQ: OSTK) is an online retailer that sells a broad range of products such as furniture, décor, rugs, bedding, electronics, apparel and home improvement items. Overstock.com also offers a marketplace that provides customers access to hundreds of thousands of products from third-party sellers. Additional stores include Worldstock.com, dedicated to selling artisan-crafted products from around the world. The retail technology company is based in Salt Lake City, Utah. For more information, visit the company’s website at www.overstock.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news…

Continue Reading

ThursdayFeb 16, 2017 2:15 pm

Spring Bank Pharmaceuticals (SBPH) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Spring Bank Pharmaceuticals (OTC: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus. SB 9200 has been designed to selectively activate within infected cells the cellular proteins, retinoic acid-inducible gene…

Continue Reading

ThursdayFeb 16, 2017 1:45 pm

Relmada Therapeutics (NYSE: RLMD) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Relmada Therapeutics (NYSE: RLMD) is a clinical-stage biotechnology company focused on developing drugs to treat central nervous system (CNS) diseases, primarily depression and chronic pain in the United States. Its lead product candidate, d-Methadone, is being developed for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER for the management of pain; BuTab ER, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence indications; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful…

Continue Reading

ThursdayFeb 16, 2017 1:15 pm

KaloBios Pharmaceuticals (KBIO) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

KaloBios Pharmaceuticals (OTC: KBIO) develops monoclonal antibody therapeutics for the treatment of cancer in the United States. Its lead product candidate is benznidazole for the treatment of Chagas disease. The company is also developing proprietary monoclonal antibodies, including lenzilumab, which is in phase I clinical trial in patients with chronic myelomonocytic leukemia; and ifabotuzumab that has completed phase I/II clinical trial in multiple hematologic malignancies, as well as evaluating further studies of ifabotuzumab in rare solid tumors, such as glioblastoma, other brain cancers in children, and rare hematologic cancer indications. For more information, visit the company's website at www.kalobios.com. About…

Continue Reading

ThursdayFeb 16, 2017 12:45 pm

RXi Pharmaceuticals (NASDAQ: RXII) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

RXi Pharmaceuticals (NASDAQ: RXII) is a clinical-stage RNAi company that focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. Its clinical development programs include RXI-109, a self-delivering RNAi compound in phase IIa clinical trial for prevention or reduction of dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids, and in a phase I/II clinical trial in retinal scarring. RXi is also developing RXI-109 for the treatment of an ophthalmic indication, focusing on retinal and corneal scarring; and Samcyprone, in phase II clinical trial for the treatment of…

Continue Reading

ThursdayFeb 16, 2017 11:45 am

AudioEye, Inc. (AEYE) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

AudioEye (OTC: AEYE) provides web accessibility solutions to Internet, print, broadcast and other media to people in the United States. The company’s solutions are designed to build accessibility into existing website or web applications; quickly conform to ADA-related standards and best practices; outsource burden of accessibility in time and money-saving manners; and to bridge the gap until accessibility issues can be fixed at the source. The AudioEye Digital Accessibility Platform is designed to be the developer’s comprehensive web accessibility tool. This tool empowers auditors, designers, and developers to understand issues of accessibility and improve website infrastructure through the use of…

Continue Reading

ThursdayFeb 16, 2017 11:45 am

Rexahn Pharmaceuticals, Inc. (NYSE: RNN) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Rexahn Pharmaceuticals (NYSE: RNN) is a clinical stage biopharmaceutical company that discovers, develops, and commercializes treatments for cancer. The company’s clinical stage oncology candidates include Archexin that completed a pilot phase II a clinical trial for the treatment of pancreatic cancer; RX-3117, which is in phase I b clinical trial for the treatment of patients with solid tumors; and Supinoxin that is in phase I clinical trial for patients with solid tumors. It is also involved in developing RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, which is in pre-clinical development stage used for the treatment of tumors. For more information visit the company’s…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000